Immune checkpoint inhibitors (ICIs) have made a breakthrough in the treatment of different types of tumors, leading to improvement in survival, even in patients with advanced cancers. Despite the good clinical results, a certain percentage of patients do not respond to this kind of immunotherapy. In addition, in a fraction of nonresponder patients, which can vary from 4 to 29% according to different studies, a paradoxical boost in tumor growth after ICI administration was observed: a completely unpredictable novel pattern of cancer progression defined as hyperprogressive disease. Since this clinical phenomenon has only been recently described, a universally accepted clinical definition is lacking, and major efforts have been made to uncover the biological bases underlying hyperprogressive disease. The lines of research pursued so far have focused their attention on the study of the immune tumor microenvironment or on the analysis of intrinsic genomic characteristics of cancer cells producing data that allowed us to formulate several hypotheses to explain this detrimental effect related to ICI therapy. The aim of this review is to summarize the most important works that, to date, provide important insights that are useful in understanding the mechanistic causes of hyperprogressive disease.

Mechanisms of hyperprogressive disease after immune checkpoint inhibitor therapy: what we (don’t) know / S. Camelliti, V. Le Noci, F. Bianchi, C. Moscheni, F. Arnaboldi, N. Gagliano, A. Balsari, M.C. Garassino, E. Tagliabue, L. Sfondrini, M. Sommariva. - In: JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH. - ISSN 1756-9966. - 39:1(2020 Nov 09), pp. 236.1-236.20. [10.1186/s13046-020-01721-9]

Mechanisms of hyperprogressive disease after immune checkpoint inhibitor therapy: what we (don’t) know

S. Camelliti
Primo
;
V. Le Noci
Secondo
;
F. Bianchi;C. Moscheni;F. Arnaboldi;N. Gagliano;A. Balsari;L. Sfondrini
Penultimo
;
M. Sommariva
Ultimo
2020

Abstract

Immune checkpoint inhibitors (ICIs) have made a breakthrough in the treatment of different types of tumors, leading to improvement in survival, even in patients with advanced cancers. Despite the good clinical results, a certain percentage of patients do not respond to this kind of immunotherapy. In addition, in a fraction of nonresponder patients, which can vary from 4 to 29% according to different studies, a paradoxical boost in tumor growth after ICI administration was observed: a completely unpredictable novel pattern of cancer progression defined as hyperprogressive disease. Since this clinical phenomenon has only been recently described, a universally accepted clinical definition is lacking, and major efforts have been made to uncover the biological bases underlying hyperprogressive disease. The lines of research pursued so far have focused their attention on the study of the immune tumor microenvironment or on the analysis of intrinsic genomic characteristics of cancer cells producing data that allowed us to formulate several hypotheses to explain this detrimental effect related to ICI therapy. The aim of this review is to summarize the most important works that, to date, provide important insights that are useful in understanding the mechanistic causes of hyperprogressive disease.
Settore MED/04 - Patologia Generale
Settore BIO/16 - Anatomia Umana
Settore BIO/17 - Istologia
Settore MED/06 - Oncologia Medica
9-nov-2020
nov-2020
Article (author)
File in questo prodotto:
File Dimensione Formato  
Camelliti_et_al-2020-Journal_of_Experimental_&_Clinical_Cancer_Research.pdf

accesso aperto

Descrizione: Articolo principale
Tipologia: Publisher's version/PDF
Dimensione 3.75 MB
Formato Adobe PDF
3.75 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/786406
Citazioni
  • ???jsp.display-item.citation.pmc??? 16
  • Scopus 37
  • ???jsp.display-item.citation.isi??? 35
social impact